SCHEMBL4770024

SCHEMBL4770024

OC1CCN(c2[c]cncc2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.37
MAPK12 P53778 2/20 0.36
MAPK13 O15264 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
PRKCZ Q05513 1/20 0.33
SMPD3 Q9NY59 2/20 0.33
KCNMA1 Q12791 1/20 0.33
CYP46A1 Q9Y6A2 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
CDK1 P06493 2/20 0.32
CDK2 P24941 2/20 0.32
NAMPT P43490 1/20 0.32
SMO Q99835 1/20 0.32
SMARCA2 P51531 1/20 0.31
SMARCA4 P51532 1/20 0.31
PBRM1 Q86U86 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468018 0.80 CHKA (0.48) MAPTLMNAHTTCDC7ROCK2
SCHEMBL4467284 0.78 CHKA (0.47) MAPTLMNAHTTROCK2MAPK1
SCHEMBL17595113 0.75 PLD1 (0.53) PRKD1ROCK2PRKCDROCK1
SCHEMBL1880062 0.75 AR (0.41) MAPTLMNAHTTPIK3CAROCK2
SCHEMBL5655784 0.73 KCNA3 (0.38) MAPTMAPK12LMNACDK1CDK2
SCHEMBL11908031 0.72 PRKCB (0.44) ROCK2PIM1PRKCDROCK1CDC42BPA
SCHEMBL206718 0.72 CHKA (0.59) MAPTMAPK12MAPK13MAPK11MAPK14
SCHEMBL29699634 0.67 SORD (0.53) MAPTSMPD3LMNAHTTJAK2
SCHEMBL17208274 0.67 SORD (0.53) MAPTSMPD3LMNAHTTJAK2
SCHEMBL6403521 0.66 CHKA (0.50) MAPTMAPK12MAPK13MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP claimed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US claimed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO claimed
EP-1991530-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265256-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-11-15 US disclosed
WO-2007098169-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265256-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A MAPT 3278/4885MAPK12 2322/4885MAPK13 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.